More Stories

Informist, Friday, May 30, 2025

MUMBAI – After a mixed earnings season in the March quarter, shares of pharmaceutical companies look robust next week, with multiple players preparing to launch products in the glucagon-like peptide-1 segment to capture a larger market share in the US, according to domestic brokerages. 

Analysts at domestic brokerages said companies such as Ajanta Pharma and Glenmark Pharmaceuticals appear well-positioned, backed by a strong product pipeline, strategic expansion, and a focus on high-margin offerings. Despite near-term earnings softness for some large caps, analysts see a clear path to margin recovery and scalable growth driven by differentiated portfolios and long-term structural drivers, which might drive a positive sentiment in the market. 

The Nifty Pharma ended marginally higher this week, outperforming the benchmark indices. The Nifty Pharma index closed at 21442.05 points on Friday, down 0.7%, with Aurobindo Pharma, Alkem Laboratories, and Ajanta Pharma being the worst performers. All three companies reported lower-than-expected earnings for the March quarter. The best-performing stocks in the index were Gland Pharma, Laurus Labs, and Glenmark Pharmaceutical. 

Focus will also be on sector heavyweights Cipla and Dr. Reddy's Laboratories, as both companies recently received observations from the US Food and Drug Administration. Cipla Friday reported that it got a Form 483 from the US regulatory body for its manufacturing facility in Bengaluru. The company said that it will address the issue raised by the FDA within the given time. 

Dr. Reddy's had said Monday that it received a Form 483 for its active pharmaceutical ingredient facility in Telangana. Form 483 is an official "notice of inspectional observations" issued by the FDA following an inspection of a regulated facility.

Companies such as Divi's Laboratories, Piramal Pharma, and Concord Biotech will also be radar as they are expected to expand margins in FY26 as they gear up to ramp up capacities to meet rising global demand.

TOP HEADLINES

* Alembic Pharma gets final nod from US FDA for generic of Bosulif tablets
* US FDA completes inspection at Alivus Life's Dahej unit with no observation
* AstraZeneca Pharma gets drug body OK to import Benralizumab solution
* Concord Biotech Jan-Mar consol PAT rises 47.8% YoY to INR 1.4 billion
* Analyst Concall: Alkem Lab EBITDA margin growth seen flat in FY26
* Earnings Review: Alkem Labs' consol PAT up 4% on yr, but misses Street view
* Wockhardt consol net loss narrows on year to INR 250 million in Jan-Mar
* Ipca Labs posts net loss of INR 650.5 mln for Jan-Mar on one-time loss
* AstraZeneca Pharma gets drug body OK to import Osimertinib tablets
* Cohance Life Jan-Mar consol PAT falls 21.3% YoY to INR 420.1 million
* US FDA gives 'Fast Track Designation' to Zydus Life's Usnoflast
* Natco Pharma Jan-Mar consol PAT rises 5.3% YoY to INR 4.07 billion
* Granules India Jan-Mar consol PAT rises over 17% YoY to INR 1.52 billion
* Earnings Outlook: Alkem Lab's revenue, PAT seen up on higher domestic sales
* Analyst Concall: Aurobindo Pharma sees high single-digit revenue growth FY26
* Earnings Review: Aurobindo Pharma PAT misses view on sharp rise in taxes
* Aurobindo Pharma estimates loss of INR 40 mln due to fire at arm's mfg unit
* Dabur board approves merger with Ayurvedic products company Sesa Care
* Akums Drugs posts net profit of INR 275.89 mln for Jan-Mar vs loss year ago
* Lupin, SteinCares ink pact to supply Ranibizumab biosimilar in Latin America
* Biocon arm gets UK drug regulator's OK to market Ustekinumab biosimilar
* Dr Reddy's Telangana API facility gets two observations from US FDA
* Cohance Life gets US FDA voluntary action indicated tag for Telangana unit
* Divi's Labs, global pharma co in pact to make, supply advanced intermediates
* Earnings Review: Glenmark Pharma PAT misses Street view due to one-time cost
* Lupin arm converts $41 mln loan, $3.3 mln interest to Lupin Oncology equity
* Sun Pharma to invest up to $25 mln in US-based Pharmazz
* Zydus Life gets US FDA final approval for Isotretinoin capsules
 

Following are the resistance and support levels for the stocks for next week as per calculations by Informist based on their prices on the National Stock Exchange:

End

Reported by P Madhu Kumar

Edited by Saji George Titus

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd by NSE Data & Analytics Ltd, a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt Ltd.

Informist Media Tel +91 (22) 6985-4000/+91 (11) 4220-1000

Send comments to feedback@informistmedia.com

© Informist Media Pvt. Ltd. 2025. All rights reserved.